103 related articles for article (PubMed ID: 15857986)
1. Amino acid 36 in the human immunodeficiency virus type 1 gp41 ectodomain controls fusogenic activity: implications for the molecular mechanism of viral escape from a fusion inhibitor.
Kinomoto M; Yokoyama M; Sato H; Kojima A; Kurata T; Ikuta K; Sata T; Tokunaga K
J Virol; 2005 May; 79(10):5996-6004. PubMed ID: 15857986
[TBL] [Abstract][Full Text] [Related]
2. Mutations of conserved glycine residues within the membrane-spanning domain of human immunodeficiency virus type 1 gp41 can inhibit membrane fusion and incorporation of Env onto virions.
Miyauchi K; Curran R; Matthews E; Komano J; Hoshino T; Engelman DM; Matsuda Z
Jpn J Infect Dis; 2006 Apr; 59(2):77-84. PubMed ID: 16632906
[TBL] [Abstract][Full Text] [Related]
3. Role of envelope processing and gp41 membrane spanning domain in the formation of human immunodeficiency virus type 1 (HIV-1) fusion-competent envelope glycoprotein complex.
Welman M; Lemay G; Cohen EA
Virus Res; 2007 Mar; 124(1-2):103-12. PubMed ID: 17129629
[TBL] [Abstract][Full Text] [Related]
4. The effect of the membrane-proximal tyrosine-based sorting signal of HIV-1 gp41 on viral infectivity depends on sequences within gp120.
Day JR; Van Damme N; Guatelli JC
Virology; 2006 Oct; 354(2):316-27. PubMed ID: 16905171
[TBL] [Abstract][Full Text] [Related]
5. Conserved residues in the coiled-coil pocket of human immunodeficiency virus type 1 gp41 are essential for viral replication and interhelical interaction.
Mo H; Konstantinidis AK; Stewart KD; Dekhtyar T; Ng T; Swift K; Matayoshi ED; Kati W; Kohlbrenner W; Molla A
Virology; 2004 Nov; 329(2):319-27. PubMed ID: 15518811
[TBL] [Abstract][Full Text] [Related]
6. Protein design of a bacterially expressed HIV-1 gp41 fusion inhibitor.
Deng Y; Zheng Q; Ketas TJ; Moore JP; Lu M
Biochemistry; 2007 Apr; 46(14):4360-9. PubMed ID: 17371053
[TBL] [Abstract][Full Text] [Related]
7. Human immunodeficiency virus (HIV) gp41 escape mutants: cross-resistance to peptide inhibitors of HIV fusion and altered receptor activation of gp120.
Desmezieres E; Gupta N; Vassell R; He Y; Peden K; Sirota L; Yang Z; Wingfield P; Weiss CD
J Virol; 2005 Apr; 79(8):4774-81. PubMed ID: 15795263
[TBL] [Abstract][Full Text] [Related]
8. Role of the specific amino acid sequence of the membrane-spanning domain of human immunodeficiency virus type 1 in membrane fusion.
Miyauchi K; Komano J; Yokomaku Y; Sugiura W; Yamamoto N; Matsuda Z
J Virol; 2005 Apr; 79(8):4720-9. PubMed ID: 15795258
[TBL] [Abstract][Full Text] [Related]
9. Susceptibility to virus-cell fusion at the plasma membrane is reduced through expression of HIV gp41 cytoplasmic domains.
Malinowsky K; Luksza J; Dittmar MT
Virology; 2008 Jun; 376(1):69-78. PubMed ID: 18400243
[TBL] [Abstract][Full Text] [Related]
10. The dominant-negative action of a fusion protein containing the cytoplasmic domain of human immunodeficiency virus type 1 transmembrane protein gp41 in virus replication.
Chan WE; Chen SS
J Biomed Sci; 2007 Nov; 14(6):717-29. PubMed ID: 17610148
[TBL] [Abstract][Full Text] [Related]
11. Functional characteristics of the natural polymorphisms of HIV-1 gp41 in HIV-1 isolates from enfuvirtide-naïve Korean patients.
Shin Y; Yoon CH; Yang HJ; Lim H; Choi BS; Kim SS; Kang C
Arch Virol; 2016 Jun; 161(6):1547-57. PubMed ID: 26997611
[TBL] [Abstract][Full Text] [Related]
12. X-ray crystallographic study of an HIV-1 fusion inhibitor with the gp41 S138A substitution.
Watabe T; Terakawa Y; Watanabe K; Ohno H; Nakano H; Nakatsu T; Kato H; Izumi K; Kodama E; Matsuoka M; Kitaura K; Oishi S; Fujii N
J Mol Biol; 2009 Sep; 392(3):657-65. PubMed ID: 19616557
[TBL] [Abstract][Full Text] [Related]
13. Antiviral properties of two trimeric recombinant gp41 proteins.
Delcroix-Genête D; Quan PL; Roger MG; Hazan U; Nisole S; Rousseau C
Retrovirology; 2006 Mar; 3():16. PubMed ID: 16515685
[TBL] [Abstract][Full Text] [Related]
14. Analysis of dominant-negative effects of mutant Env proteins of human immunodeficiency virus type 1.
Iwatani Y; Kawano K; Ueno T; Tanaka M; Ishimoto A; Ito M; Sakai H
Virology; 2001 Jul; 286(1):45-53. PubMed ID: 11448157
[TBL] [Abstract][Full Text] [Related]
15. Quaternary protein mimetics of gp41 elicit neutralizing antibodies against HIV fusion-active intermediate state.
Sadler K; Zhang Y; Xu J; Yu Q; Tam JP
Biopolymers; 2008; 90(3):320-9. PubMed ID: 18338371
[TBL] [Abstract][Full Text] [Related]
16. The first B/G intersubtype recombinant form of human immunodeficiency virus type 1 (HIV-1) identified in Germany was undetected or underquantitated by some commercial viral load assays.
von Truchsess I; Harris B; Schätzl HM; Hackett J
J Med Virol; 2006 Mar; 78(3):311-7. PubMed ID: 16419111
[TBL] [Abstract][Full Text] [Related]
17. The application of perfluorooctanoate to investigate trimerization of the human immunodeficiency virus-1 gp41 ectodomain by electrophoresis.
Lin CH; Chang CC; Cheng SF; Chang DK
Electrophoresis; 2008 Aug; 29(15):3175-82. PubMed ID: 18633939
[TBL] [Abstract][Full Text] [Related]
18. Mutations at the C-terminus of the simian immunodeficiency virus envelope glycoprotein affect gp120-gp41 stability on virions.
Affranchino JL; González SA
Virology; 2006 Mar; 347(1):217-25. PubMed ID: 16380144
[TBL] [Abstract][Full Text] [Related]
19. Structural characterization of the feline-immunodeficiency-virus envelope glycoprotein 36 ectodomain for the development of new antivirals.
Desmaris F; Lemaire D; Ricard-Blum S; Chatrenet B; Forest E
Biochem J; 2005 Jul; 389(Pt 2):559-67. PubMed ID: 15799719
[TBL] [Abstract][Full Text] [Related]
20. Enhancement of human immunodeficiency virus type 1 infectivity by replacing the region including Env derived from defective particles with an ability to form particle-mediated syncytia in CD4+T cells.
Kinomoto M; Mukai T; Li YG; Iwabu Y; Warachit J; Palacios JA; Ibrahim MS; Tsuji S; Goto T; Ikuta K
Microbes Infect; 2004 Aug; 6(10):911-8. PubMed ID: 15310467
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
